Leukemias
Mixed-phenotype acute leukemia, B/myeloid
Also called: MPAL B/myeloid · biphenotypic acute leukemia · B/myeloid biphenotypic or bilineal acute leukaemia (older terms)
Classified by the World Health Organization as Mixed-phenotype acute leukaemia, B/myeloid.
What a donor has to do with this
For some people with this condition, a transplant using blood stem cells from an unrelated donor is part of the treatment guidelines. When a transplant is the right route and no one in the family matches, that donor comes from a registry. Not everyone with this condition has a transplant, and many never need one.
This is our reading of published transplant guidelines for this condition, not a measurement of how many people need a donor. Where a source actually counted donors, the figure and the people it counted are shown further down. Where none did, we say so rather than estimate.
What the evidence says
- Who it affects
- Diagnosed across childhood and adulthood but is markedly more common in adults; no consistent sex or ancestry predominance is established. Source population/region/year: international paediatric-and-adult literature synthesized in a systematic review published 2018.
- Treatments other than a transplant
- ALL-like induction is commonly used, with lineage-targeted agents when appropriate; optimal induction is unsettled and allo-HCT is the principal consolidative curative strategy in eligible responders
- If a transplant is used, the cells come from
- Allogeneic peripheral blood, bone marrow or cord blood; registry cohorts include multiple donor types; dominant source not reported in the opened disease-specific sources
- How often the donor was unrelated
- Not reported. No source we could read states this for this condition, so we do not give a number. An estimate here would be a guess dressed as evidence.
Where this gets complicated
WHO5 separates B/myeloid, T/myeloid and genetically defined MPAL. Older EGIL biphenotypic cohorts do not map perfectly to current lineage criteria.
“mixed phenotype acute leukemia is potentially sensitive to graft-versus-leukemia and thus can benefit from allogeneic hematopoietic stem cell transplantation”
It describes what teams consider in general. It cannot say what applies to any one person. Read the source.
People with this condition need donors
Joining a registry is a cheek swab and a short health form. You are contacted only if you turn out to be a possible match for someone, and you can ask questions and decline before anything else happens.
Related conditions
Others in leukemias. They are genuinely different diseases with different treatments — the group name is not a diagnosis.
Where this came from
- WHO Classification of Haematolymphoid Tumours, 5th edition — final table of contents — WHO/IARC, final print volume 2024; online classification introduced 2022
- Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation — Haematologica / EBMT ALWP, 2017-12
- Indications for haematopoietic cell transplantation and CAR-T: 2025 EBMT practice recommendations — EBMT / Bone Marrow Transplantation, 2025-09-09
- Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis — Leukemia / systematic review, 2018